Originally published in our sister publication, Pain Medicine News.
The FDA recently cleared a remote electrical neuromodulation device (Nerivio, Theranica) for acute treatment of migraine in children as young as 12 years of age. Patients can be diagnosed with either episodic or chronic migraine.
Researchers saw positive results of the device’s use in adolescents, publishing their research in the journal Headache (21 Dec 2020. [Epub ahead of print]). The device was approved for use in